Dr. Mesa on Pacritinib for Myelofibrosis

Ruben A. Mesa, MD
Published: Monday, Jun 08, 2015



Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study that examined pacribitinib as a treatment for myelofibrosis.

Myelofibrosis is a chronic myeloid neoplasm that inflicts patients with splenomegaly symptoms and potential low blood counts, Mesa explains.

The PERSIST-1 study randomized patients with the bone marrow cancer to receive pacritinib or best alternative therapy. The novel JAK2 inhibitor has demonstrated improvements in splenomegaly symptoms in previous studies, he adds. The study enrolled patients with intermediate- and high-risk disease and did not exclude patients with severe thrombocytopenia.

Results demonstrated that pacritinib was superior to the best alternative therapy in all endpoints, including one reduction in spleen volume, improvement in disease-related symptoms, and an increase in platelet counts. Twenty-five percent of patients in the study who were red blood cell transfusion dependent became transfusion independent, Mesa says.
SELECTED
LANGUAGE


Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study that examined pacribitinib as a treatment for myelofibrosis.

Myelofibrosis is a chronic myeloid neoplasm that inflicts patients with splenomegaly symptoms and potential low blood counts, Mesa explains.

The PERSIST-1 study randomized patients with the bone marrow cancer to receive pacritinib or best alternative therapy. The novel JAK2 inhibitor has demonstrated improvements in splenomegaly symptoms in previous studies, he adds. The study enrolled patients with intermediate- and high-risk disease and did not exclude patients with severe thrombocytopenia.

Results demonstrated that pacritinib was superior to the best alternative therapy in all endpoints, including one reduction in spleen volume, improvement in disease-related symptoms, and an increase in platelet counts. Twenty-five percent of patients in the study who were red blood cell transfusion dependent became transfusion independent, Mesa says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x